Colorectal Cancer | Specialty

The colorectal cancer condition center is a comprehensive resource for clinical news and expert insights on colorectal cancer. Read more at OncLive.

Efficacy of Upfront Panitumumab Plus Intensified Chemo Falls Short in Liver-Limited, Unresectable mCRC

July 7th 2025

Panitumumab plus FOLFIRINOX or mFOLFOX6 did not elicit meaningful responses in previously untreated, liver-limited, RAS/BRAF wild-type unresectable mCRC.

Real-World Analysis Reveals Shorter Survival in KRAS G12C–Mutant Metastatic CRC After First-Line Treatment

July 7th 2025

A real-world analysis showed that patients with KRAS G12C–mutant mCRC had shorter OS and PFS after first-line treatment vs those with non-G12C mutations.

Trifluridine/Tipiracil Numerically Improves DFS After Curative Resection in ctDNA+ CRC

July 5th 2025

Treatment with trifluridine/tipiracil led to an improvement in disease-free survival in ctDNA-positive colorectal cancer after curative resection.

ctDNA-Guided Surveillance Leads to Increased Curative-Intent Treatment After Recurrence in Nonmetastatic CRC

July 5th 2025

ctDNA monitoring led to earlier recurrence detection and increased use of curative-intent treatment after recurrence in nonmetastatic colorectal cancer.

Dr García-Carbonero on Outcomes With Fruquintinib in R/R mCRC by Metastatic Sites

July 5th 2025

Rocío García-Carbonero, MD, discusses a subgroup analysis of fruquintinib vs placebo in patients with refractory metastatic colorectal cancer.

Real-World Analysis Sheds Light on Fruquintinib Use in Later-Line Metastatic CRC

July 4th 2025

A real-world study in Portugal showed fruquintinib displayed a manageable safety profile and an efficacy trend in refractory colorectal cancer.

Quantitative Vessel Tortuosity Shows Potential as Biomarker for Antiangiogenic Activity With Fruquintinib in mCRC

July 4th 2025

Quantitative vessel tortuosity features were able to detect the VEGFR inhibitory mechanism of fruquintinib in metastatic colorectal cancer.

Survival Benefit, Neutropenia Risk Influence Third-Line Treatment Preferences for mCRC in Germany and the UK

July 4th 2025

A survey of UK and German physicians found that OS gains were needed to accept increased toxicities or treatment burden with third-line regimens in mCRC.

Dr Schlechter on Updated Data for Botensilimab Plus Balstilimab in MSS mCRC

July 4th 2025

Benjamin L. Schlechter, MD, discusses efficayc and safety of botensilimab in combination with the anti–PD-1 antibody balstilimab in mCRC.

Subgroup Analysis Supports Encorafenib Plus Cetuximab/mFOLFOX6 as New SOC for BRAF V600E+ mCRC

July 4th 2025

Post hoc analyses compared encorafenib plus cetuximab and mFOLFOX6 with different BREAKWATER control arm regimens.

Fruquintinib Demonstrates Clinical Benefit in mCRC Irrespective of Metastatic Sites at Baseline

July 4th 2025

A post hoc subgroup analysis of FRESCO-2 shed light on the safety and efficacy of fruquintinib by metastatic site in metastatic colorectal cancer.

Nivolumab Plus Ipilimumab Improves HRQOL Vs Nivolumab Alone in MSI-H/dMMR mCRC

July 3rd 2025

CheckMate 8HW data show ipilimumab plus nivolumab improved PFS vs nivolumab alone while maintaining HRQOL.

Biomarker-Directed Therapies Improve Outlooks for the mCRC Treatment Arsenal: With Chandler Park, MD; and Midhun Malla, MD

July 2nd 2025

Drs Park and Malla discuss therapeutic options for patients with metastatic colorectal cancer, particularly in the third-line setting and beyond.

A Review of the Treatment Options in Third-Line mCRC and Therapy Sequencing Strategies

June 30th 2025

Panelists discuss how 3 drugs (regorafenib, TAS-102, and fruquintinib) offer modest but meaningful survival benefits in treatment-refractory colorectal cancer, with TAS-102 plus bevacizumab being the preferred combination when tolerated.

The Role of ctDNA in the Management of mCRC

June 30th 2025

Panelists discuss how circulating tumor DNA testing serves as the best prognostic technology available, particularly useful for identifying high-risk stage II patients who would benefit from adjuvant therapy, though surveillance strategies for positive results remain unclear.

The OncFive: Top Oncology Articles for the Week of 6/22

June 28th 2025

The FDA grants approval to Dato-DXd in EGFR+ NSCLC, revumenib sNDA is under priority review for NPM1-mutant AML, and more from OncLive this week.

Zanzalintinib Plus Atezolizumab Boosts OS in Previously Treated, Non–MSI-H mCRC

June 23rd 2025

Zanzalintinib plus atezolizumab improved overall survival in previously treated, non–MSI-H metastatic colorectal cancer.

CheckMate 8HW Expanded Analysis at ASCO 2025: Implications for Treatment Decisions in MSI-H mCRC

June 23rd 2025

Panelists discuss how doublet immunotherapy with ipilimumab and nivolumab provides superior outcomes compared to single-agent PD-1 therapy or chemotherapy in microsatellite instability-high colorectal cancer, supporting the “hit hard, hit early” approach.

Expert Insights: BREAKWATER Survival Data Update From ASCO 2025

June 23rd 2025

Panelists discuss how the BREAKWATER trial demonstrates that upfront treatment with encorafenib plus cetuximab significantly improves outcomes in BRAF V600E-mutated colorectal cancer, turning a historically poor prognostic marker into a targetable opportunity.

Dr Arnold on the Evaluation of Chemo With Amivantamab or Cetuximab in RAS/BRAF Wild-Type mCRC

June 19th 2025

Dirk Arnold, MD, PhD, on the investigation of amivantamab vs cetuximab, both in combination with chemotherapy, in RAS/BRAF wild-type mCRC.